Response to letter to the editor: “Comments on ‘discrepancies between validated GC‐FID and UHPLC‐DAD methods for the analysis of Δ‐9‐THC and CBD in dried hemp flowers’”

Drug Testing and AnalysisVolume 15, Issue 2 p. 247-249 LETTER TO THE EDITOR Response to letter to the editor: “Comments on ‘discrepancies between validated GC-FID and UHPLC-DAD methods for the analysis of Δ-9-THC and CBD in dried hemp flowers’” Eric Deconinck, Corresponding Author Eric Deconinck eric.deconinck@sciensano.be orcid.org/0000-0001-6980-6684 Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, Brussels, Belgium Pharmacognosy, Bioanalysis & Drug Discovery, Faculty of Pharmacy, ULB, Brussels, Belgium Correspondence Eric Deconinck, Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, Sciensano, J. Wytsmanstraat 14, B-1050 Brussels, Belgium. Email: eric.deconinck@sciensano.beSearch for more papers by this authorMichaël Canfyn, Michaël Canfyn Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, Brussels, BelgiumSearch for more papers by this authorCéline Duchateau, Céline Duchateau Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, Brussels, Belgium Pharmacognosy, Bioanalysis & Drug Discovery, Faculty of Pharmacy, ULB, Brussels, BelgiumSearch for more papers by this authorKris De Braekeleer, Kris De Braekeleer orcid.org/0000-0002-3910-2990 Pharmacognosy, Bioanalysis & Drug Discovery, Faculty of Pharmacy, ULB, Brussels, BelgiumSearch for more papers by this author Eric Deconinck, Corresponding Author Eric Deconinck eric.deconinck@sciensano.be orcid.org/0000-0001-6980-6684 Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, Brussels, Belgium Pharmacognosy, Bioanalysis & Drug Discovery, Faculty of Pharmacy, ULB, Brussels, Belgium Correspondence Eric Deconinck, Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, Sciensano, J. Wytsmanstraat 14, B-1050 Brussels, Belgium. Email: eric.deconinck@sciensano.beSearch for more papers by this authorMichaël Canfyn, Michaël Canfyn Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, Brussels, BelgiumSearch for more papers by this authorCéline Duchateau, Céline Duchateau Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, Brussels, Belgium Pharmacognosy, Bioanalysis & Drug Discovery, Faculty of Pharmacy, ULB, Brussels, BelgiumSearch for more papers by this authorKris De Braekeleer, Kris De Braekeleer orcid.org/0000-0002-3910-2990 Pharmacognosy, Bioanalysis & Drug Discovery, Faculty of Pharmacy, ULB, Brussels, BelgiumSearch for more papers by this author First published: 21 October 2022 https://doi.org/10.1002/dta.3388Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume15, Issue2February 2023Pages 247-249 RelatedInformation